What are the Kenyan diabetes guidelines for screening, diagnosis, and management of diabetes?

Kenyan Diabetes Guidelines: Screening, Diagnosis, and Management

Kenya lacks nationally published, Kenya-specific diabetes clinical practice guidelines in the provided evidence, but healthcare facilities should follow internationally recognized standards adapted to local resource constraints, with screening beginning at age 35 or earlier for those with risk factors, diagnosis confirmed by HbA1c ≥6.5% or fasting glucose ≥126 mg/dL on two occasions, and management prioritizing cardiovascular risk reduction alongside glycemic control.

Critical Context for Kenya

The reality in Kenya differs substantially from high-resource settings. Only 24.1% of Kenyan healthcare facilities are ready to provide integrated diabetes and cardiovascular disease care 1. Public facilities and primary healthcare centers show particularly poor readiness compared to private facilities and hospitals 1. This means recommendations must be pragmatic and acknowledge resource limitations.

Screening Recommendations

Who to Screen

Begin screening at age 35 years for all adults, or earlier if overweight/obese (BMI ≥25 kg/m²) with any of these risk factors 2:

• First-degree relative with diabetes
• Hypertension (≥130/80 mmHg or on treatment)
• History of cardiovascular disease
• HDL cholesterol <35 mg/dL or triglycerides >250 mg/dL
• Physical inactivity
• Polycystic ovary syndrome
• Acanthosis nigricans

For patients with hypertension or hyperlipidemia, screen for diabetes regardless of other factors 3.

Screening Frequency

• If normal: repeat every 3 years minimum 2
• If prediabetes detected: monitor at least annually 4
• Sooner if symptoms develop or weight gain occurs 2

Screening Methods (Choose Based on Availability)

In order of preference for Kenyan settings:

1. Fasting plasma glucose (FPG) - requires 8-hour fast, most cost-effective at ~$6 3
2. HbA1c - no fasting required, but requires NGSP-certified laboratory 5
3. Oral glucose tolerance test (OGTT) - gold standard but requires 75g glucose load, 2-hour wait, poor patient compliance 3, 6

Random glucose testing has limited utility (sensitivity only 39-55%) but values ≥140 mg/dL warrant definitive testing 3.

Diagnostic Criteria

Diabetes is diagnosed when ANY of the following occur on two separate occasions 3, 7:

• HbA1c ≥6.5% (must use NGSP-certified method in accredited laboratory) 5
• Fasting plasma glucose ≥126 mg/dL (7.0 mmol/L) after 8-hour fast 3, 6
• 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during 75g OGTT 6
• Random plasma glucose ≥200 mg/dL (11.1 mmol/L) with classic symptoms (polyuria, polydipsia, weight loss, blurred vision, fatigue) 3

Prediabetes Categories

Identify patients at increased risk 3, 2:

• Impaired fasting glucose: FPG 100-125 mg/dL (5.6-6.9 mmol/L)
• Impaired glucose tolerance: 2-hour OGTT 140-199 mg/dL (7.8-11.0 mmol/L)
• HbA1c 5.7-6.4% (39-46 mmol/mol)

Management Framework

Glycemic Targets

HbA1c <7% (<53 mmol/mol) for most non-pregnant adults 5. However, individualize based on:

• More stringent (<6.5%) if achievable without hypoglycemia and early in disease course
• Less stringent (7.5-8%) for: limited life expectancy, extensive comorbidities, history of severe hypoglycemia, advanced complications 5

Treatment Algorithm Priority

Given Kenya's high cardiovascular disease burden, prioritize medications with proven cardiovascular and renal benefits over glucose-lowering alone 8, 9:

First-Line for Patients WITH Established ASCVD, Heart Failure, or CKD:

1. Metformin (if eGFR adequate and tolerated) PLUS
2. GLP-1 receptor agonist (cardiovascular benefit proven) OR SGLT2 inhibitor (cardiovascular and renal benefit proven)

First-Line for Patients WITHOUT Established Complications:

1. Metformin as initial pharmacotherapy
2. Add second agent if HbA1c remains ≥7% after 3 months based on:
   • Weight: If overweight/obese, add GLP-1 agonist or SGLT2 inhibitor
   • Cost/availability: Sulfonylureas if cost-prohibitive (monitor for hypoglycemia)
   • Hypoglycemia risk: Avoid sulfonylureas in elderly or those at high risk

Cardiovascular Risk Management

Treat hypertension aggressively: target <130/80 mmHg 8:

• ACE inhibitors or ARBs for patients with albuminuria or eGFR <60 mL/min/1.73m² 8

Statin therapy 8:

• High-intensity statin for age 40-75 with diabetes and ASCVD
• Moderate-intensity statin for age 40-75 with diabetes without ASCVD
• Consider for age 20-39 with additional risk factors

Aspirin 75-162 mg/day for secondary prevention in those with known ASCVD 8

Monitoring Schedule

• HbA1c every 3 months until target achieved, then every 6 months 5
• Annual screening for complications 8:
  • Urine albumin-creatinine ratio and eGFR (kidney disease)
  • Comprehensive eye examination by ophthalmologist/optometrist
  • Foot examination for neuropathy and vascular disease
  • Lipid profile

Lifestyle Interventions (Non-Negotiable Foundation)

• Weight loss of 5-7% for all overweight/obese patients 10, 4
• 150 minutes/week moderate-intensity aerobic activity spread over ≥3 days 10
• Resistance training twice weekly 10
• Medical nutrition therapy - refer to dietitian when available 10

Common Pitfalls in Kenyan Context

1. Delayed diagnosis: With 40% of diabetes undiagnosed globally 7, aggressive community screening is essential, particularly in rural areas 11

2. Supply chain disruptions: Inconsistent medication availability requires backup treatment plans 1, 12

3. Limited specialist access: Primary care physicians must manage most cases - web-based training programs have proven effective for knowledge improvement 13

4. Poor integration: Diabetes care often fragmented from cardiovascular and renal care despite overlapping pathophysiology 1, 12

5. Inadequate patient education: Diabetes self-management education is frequently unavailable but critical for outcomes 12

6. Using urine glucose testing: This is not recommended for routine diabetes care 5

Practical Adaptations for Resource-Limited Settings

When HbA1c unavailable: Use fasting glucose for diagnosis and monitoring 3

When OGTT impractical: Accept fasting glucose alone, understanding some cases will be missed 3

When newer agents unaffordable: Metformin plus sulfonylurea remains acceptable, but monitor closely for hypoglycemia 9

When specialist referral impossible: Primary care must manage complications using available resources and telemedicine when possible 13